Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 4,250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Head Clear all
Recruiting Not applicable Interventional

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

NCT05775939
View directory record Official record
Conditions
Lung Carcinoma, Esophageal Carcinoma
Interventions
Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Questionnaire Administration
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT06919666
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
NT219
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Aurora, Colorado • Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Recruiting Phase 1 Interventional

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

NCT03740256
View directory record Official record
Conditions
Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
Interventions
CAdVEC
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.

NCT01715233
View directory record Official record
Conditions
Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer
Interventions
Docetaxel, Leucovorin, Fluorouracil, Cisplatin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

NCT02219711
View directory record Official record
Conditions
Advanced Cancer
Interventions
MGCD516
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 18, 2026, 11:12 AM EDT
Recruiting Phase 4 Interventional

Sufentanil Infusion vs Intravenous Methadone for Postoperative Analgesia Following Head and Neck Dissection With Free Flap or Rotational Reconstruction

NCT06784999
View directory record Official record
Conditions
Free Flap Reconstruction
Interventions
sufentanil, methadone
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT06305247
View directory record Official record
Conditions
Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Interventions
IPN01194
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

NCT05099549
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor
Interventions
AFM24, SNK01
Drug · Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 18, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional Results available

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

NCT01009203
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Erlotinib, Temsirolimus
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 18, 2026, 11:12 AM EDT
Withdrawn Not applicable Interventional

Attention Intervention Management

NCT01779427
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Attention Deficit Hyperactivity Disorder (ADHD), Head Injury, Brain Concussion, Head Injuries, Closed
Interventions
AIM
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

NCT00006033
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene therapy, interleukin-2 gene, methotrexate
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 18, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

NCT07795749
View directory record Official record
Conditions
Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma, Small Bowel Adenocarcinoma, Hepatobiliary Carcinoma in Situ
Interventions
Paclitaxel Q2W, Paclitaxcel Q3W
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional

Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck

NCT00216138
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Capecitabine, Premedication
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
18
States / cities
Newark, Delaware • Chicago, Illinois • Elkhart, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 18, 2026, 11:12 AM EDT
Recruiting No phase listed Observational

Recovery Among Older Adults Following Mild TBI

NCT07569354
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
65 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Not listed Not applicable Interventional

Portable Mixed Reality-based Platform for Assessment of Progress in Multisensory Rehabilitation Strategies Post-TBI

NCT06314464
View directory record Official record
Conditions
Brain Concussion, Vestibular Disorder, Cognition Disorder, Mild Traumatic Brain Injury
Interventions
Praxis, Supervised cardiovascular exercise
Device · Behavioral
Lead sponsor
BlueHalo
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 3 Interventional

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

NCT00020787
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
G17DT Immunogen, cisplatin, fluorouracil
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

NCT02007200
View directory record Official record
Conditions
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma, Stage I Laryngeal Verrucous Carcinoma, Stage I Lip and Oral Cavity Squamous Cell Carcinoma, Stage I Oral Cavity Verrucous Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Verrucous Carcinoma, Stage II Lip and Oral Cavity Squamous Cell Carcinoma, Stage II Oral Cavity Verrucous Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Laryngeal Verrucous Carcinoma, Stage III Lip and Oral Cavity Squamous Cell Carcinoma, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions
Laboratory Biomarker Analysis, Soy Isoflavones, Survey Administration
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years to 79 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 18, 2026, 11:12 AM EDT
Recruiting Phase 1Phase 2 Interventional

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

NCT07667400
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Carcinoma of Larynx, Oral Squamous Cell Carcinoma, Salivary Gland Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions
SX-682, DTX
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Recruiting No phase listed Observational

A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy

NCT05207098
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Neurocognitive Tests, Questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Withdrawn Not applicable Interventional

Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Trial)

NCT02109198
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Active CN-NINM PoNS, Sham CN-NINM PoNS
Device
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 18, 2026, 11:12 AM EDT
Completed No phase listed Observational

Whole-Body MRI in Suspected Victims of Abusive Head Trauma

NCT02309216
View directory record Official record
Conditions
Shaken Baby Syndrome
Interventions
Whol-Body MRI scan
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 12 Months
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 18, 2026, 11:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Consistency of Automated Neuropsychological Assessment Metrics (ANAM) Performance in Those With Deployment Acquired Mild Traumatic Brain Injury (TBI)

NCT01334528
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Post-Concussive Symptoms
Interventions
Not listed
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Not applicable Interventional Results available

A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation

NCT00847509
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer
Interventions
[F-18]FLT
Drug
Lead sponsor
Siemens Molecular Imaging
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Oct 18, 2026, 11:12 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The TCU Division I Collegiate Athlete Study

NCT07006051
View directory record Official record
Conditions
Orthopaedic Injuries, Concussion (Diagnosis)
Interventions
Exposed group
Other
Lead sponsor
Texas Christian University
Other
Eligibility
17 Years to 30 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 18, 2026, 11:12 AM EDT